161 related articles for article (PubMed ID: 1988232)
1. Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro.
Hollander AP; Atkins RM; Eastwood DM; Dieppe PA; Elson CJ
Clin Exp Immunol; 1991 Jan; 83(1):52-7. PubMed ID: 1988232
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of normal and arthritic human articular cartilage to degradative stimuli.
Ismaiel S; Atkins RM; Pearse MF; Dieppe PA; Elson CJ
Br J Rheumatol; 1992 Jun; 31(6):369-73. PubMed ID: 1596698
[TBL] [Abstract][Full Text] [Related]
3. Degradation of human cartilage by synovial fluid but not cytokines in vitro.
Hollander AP; Atkins RM; Eastwood DM; Dieppe PA; Elson CJ
Ann Rheum Dis; 1991 Jan; 50(1):57-8. PubMed ID: 1994871
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid synovial fluid contains bioactive leukemia inhibitory factor with cartilage degrading activity--another target for chondroprotective intervention.
Bell MC; Carroll GJ
J Rheumatol; 2000 Feb; 27(2):332-8. PubMed ID: 10685793
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of insulin-like growth factor (IGF) binding protein-3 in rheumatoid arthritis synovial fluid inhibit stimulation by IGF-I of articular chondrocyte proteoglycan synthesis.
Neidel J; Blum WF; Schaeffer HJ; Schulze M; Schönau E; Lindschau J; Föll J
Rheumatol Int; 1997; 17(1):29-37. PubMed ID: 9194211
[TBL] [Abstract][Full Text] [Related]
6. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
7. Hypothesis: cartilage catabolic cofactors in human arthritis.
Hollander AP; Dieppe PA; Atkins RM; Elson CJ
J Rheumatol; 1993 Feb; 20(2):223-4. PubMed ID: 8474056
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of glycosaminoglycans in synovial fluids and their relation with immunological and inflammatory mediators in rheumatoid arthritis.
Bensouyad A; Hollander AP; Dularay B; Bedwell AE; Cooper RA; Hutton CW; Dieppe PA; Elson CJ
Ann Rheum Dis; 1990 May; 49(5):301-7. PubMed ID: 2344209
[TBL] [Abstract][Full Text] [Related]
9. Differential responses of human and rat cartilage to degrading stimuli in-vitro.
Ismaiel S; Hollander AP; Atkins RM; Elson CJ
J Pharm Pharmacol; 1991 Mar; 43(3):207-9. PubMed ID: 1675281
[TBL] [Abstract][Full Text] [Related]
10. The role of cytokines in arthritic diseases: in vitro and in vivo measurements of cartilage degradation.
Dingle JT; Page Thomas DP; Hazleman B
Int J Tissue React; 1987; 9(4):349-54. PubMed ID: 3497901
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: Attenuated the production of inflammatory cytokines.
Xia L; Shen H; Lu J
Cytokine; 2015 Dec; 76(2):553-557. PubMed ID: 26159110
[TBL] [Abstract][Full Text] [Related]
12. Synovial fluid from rheumatoid arthritis patients contains sufficient levels of IL-1 beta and IL-6 to promote production of serum amyloid A by Hep3B cells.
McNiff PA; Stewart C; Sullivan J; Showell HJ; Gabel CA
Cytokine; 1995 Feb; 7(2):209-19. PubMed ID: 7780041
[TBL] [Abstract][Full Text] [Related]
13. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4.
van Roon JA; van Roy JL; Gmelig-Meyling FH; Lafeber FP; Bijlsma JW
Arthritis Rheum; 1996 May; 39(5):829-35. PubMed ID: 8639180
[TBL] [Abstract][Full Text] [Related]
14. Detection of tumour necrosis factor alpha and interleukin-1 beta in the rheumatoid osteoarthritic cartilage-pannus junction by immunohistochemical methods.
Miller VE; Rogers K; Muirden KD
Rheumatol Int; 1993; 13(2):77-82. PubMed ID: 8356394
[TBL] [Abstract][Full Text] [Related]
15. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
16. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
[TBL] [Abstract][Full Text] [Related]
18. [Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis].
Neidel J; Schulze M; Sova L; Lindschau J
Z Orthop Ihre Grenzgeb; 1996; 134(4):381-5. PubMed ID: 8928570
[TBL] [Abstract][Full Text] [Related]
19. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis.
Koch AE; Kunkel SL; Harlow LA; Mazarakis DD; Haines GK; Burdick MD; Pope RM; Walz A; Strieter RM
J Clin Invest; 1994 Sep; 94(3):1012-8. PubMed ID: 8083342
[TBL] [Abstract][Full Text] [Related]
20. Direct degradation of articular cartilage by rheumatoid synovial fluid: contribution of proteolytic enzymes.
Larbre JP; Moore AR; Da Silva JA; Iwamura H; Ioannou Y; Willoughby DA
J Rheumatol; 1994 Oct; 21(10):1796-801. PubMed ID: 7837140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
